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Abstract 
Introduction: Autoimmunity occurs when the immune system recognizes and attacks host tissue. In addition to genetic factors, environmental 
triggers (in particular viruses, bacteria and other infectious pathogens) are thought to play a major role in the development of autoimmune 
diseases. 
Methodology: We searched PubMed, Cochrane, and Scopus without time limits for relevant articles. 
Results: In this review, we (i) describe the ways in which an infectious agent can initiate or exacerbate autoimmunity; (ii) discuss the 
evidence linking certain infectious agents to autoimmune diseases in humans; and (iii) describe the animal models used to study the link 
between infection and autoimmunity. 
Conclusions: Besides genetic predisposition to autoimmunity, viral and bacterial infections are known to be involved in the initiation and 
promotion of autoimmune diseases. These studies suggest that pathogens can trigger autoimmunity through molecular mimicry and their 
adjuvant effects during initiation of disease, and can promote autoimmune responses through bystander activation or epitope spreading via 
inflammation and/or superantigens. 
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Introduction 
The immune system must distinguish self from 
harmful non-self to repel invaders and to preserve the 
integrity of the host without inducing autoimmunity. 
Any deficit in this function can result in susceptibility 
to infections, malignancies [1-3] or over-reactivity to 
harmless antigens, leading to immunopathology and 
autoimmunity. The etiology of autoimmune diseases 
has been difficult to elucidate. Several factors are 
thought to contribute to the development of immune 
response to self, including genetics and environment 
[4-6] 
Several common autoimmune diseases, such as 
rheumatoid arthritis, systemic lupus erythematosus and 
multiple sclerosis, are genetically linked to distinct 
human major histocompatibility complex (MHC) class 
II molecules and other immune modulators. 
Furthermore, autoimmunity often clusters   families, 
indicating the potential for a broad-spectrum genetic 
defect in immunological tolerance mechanisms. 
However, the genetic factors leading to the 
development of immune responses against specific 
antigens in a tissue and/or organ-specific manner 
remain largely unknown. Among the environmental 
factors, infections have been implicated in the onset 
and/or promotion of autoimmunity [7]. 
This article reviews the evidence regarding the 
association of pathogens with autoimmune diseases. 
We searched PubMed, Cochrane, and Scopus without 
time limits. The following search terms were 
employed in various combinations: “bacterium”, 
“parasite”, “virus”, “infection” and “autoimmunity”. 
There are more than eighty identified autoimmune 
diseases [8]. Multiple arms of the immune system may 
be involved in autoimmune pathology. Antigens are 
taken up by antigen presenting cells (APC) such as 
dendritic cells (DC) and processed into peptides which 
are loaded onto MHC molecules for presentation to T 
cells via clonotypic T cell receptors (TCR). Cytolytic 
T cells (Tc, activated by MHC class I on APC) can 
directly lyse a target, while T helper cells (Th, 
activated by MHC class II) release cytokines that can 
have direct effects or can activate macrophages, 
monocytes and B cells. B cells themselves have 
surface receptors that can bind surface antigens. Upon 
receiving signals from Th cells, B cells secrete 
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antibodies specific for the antigens. Antibody may 
bind its specific target alone or may bind to and 
activate macrophages simultaneously via the Fc 
receptor. 
Multiple mechanisms have been described to 
explain how pathogens might induce activation and 
critical expansion of autoreactive T cells and start 
autoimmune disease [9-14]. A microbial antigen can 
include an epitope that is structurally similar to an 
autoantigen epitope, providing the basic element of the 
mechanism referred to as molecular mimicry [13-18]. 
Another mechanism would imply that the 
inflammatory setting and the paracrine secretion of T 
cell growth factors induce the expansion of activated 
autoreactive T cells, whose small number was 
previously insufficient to drive an autoimmune 
disease. Such a mechanism is referred to as bystander 
activation [19]. Pathogen-induced tissue inflammation 
may result in local activation of APC and enhanced 
processing/presentation of self-antigens that causes T 
cell priming, followed by T cell activation and 
expansion of additional specificities (epitope 
spreading) [20,21]. Activation of resting autoreactive 
T cells may be achieved by viral and bacterial 
superantigens that bind a variety of MHC class II 
molecules and activate large numbers of T cells, 
irrespective of their specificity [22]. 
In this review, we outline the mechanisms by 
which pathogens could trigger autoimmune diseases 
and the evidence available for the involvement of 
specific pathogens in the initiation or exacerbation of 
representative autoimmune diseases. 
 
Pathogen responses and autoimmunity 
The ability of the host to defend against invading 
pathogens is to a large extent mediated by a group of 
germline-encoded receptors known as pattern-
recognition receptors (PRR). These molecules include 
Toll-like receptors (TLR), nucleotide-binding and 
oligomerization domain (NOD)-like receptors (NLR), 
(RIG-I)-like helicases and a subset of C-type lectin 
receptors, which together recognize a large number of 
molecular patterns present in bacteria, viruses and 
fungi [23]. The signalling pathways that are triggered 
by engagement of these molecules lead to cellular 
activation, which increases the antigen-presenting 
capacity of and the expression of co-stimulatory 
molecules by APC, as well as their production of type 
I interferons, pro-inflammatory cytokines and 
chemokines, which initiate and direct the immune 
response against the invading pathogen. Microbial 
antigens as well as PRR-triggered inflammatory 
molecules drive the clonal expansion of pathogen-
specific T and B cells. By triggering PRRs, stimulating 
early responses by the innate immune system and 
increasing the function of APC, pathogens act as 
adjuvants for the immune response, while at the same 
time providing an antigen source to drive T-cell and 
B-cell activation. In this highly inflammatory 
environment, it is easy to envision how an aberrant 
destructive immune response can be triggered and/or 
escalated if autoreactive cells are present. There are 
several postulated mechanisms by which pathogenic 
infections can trigger autoimmune disease (Figure 1). 
 
Molecular mimicry 
Antigen recognition by the TCR allows T-cell 
activation by different peptides bound to one or even 
several MHC molecules [24]. The pathogen may carry 
elements that are similar enough in amino acid 
sequence or structure to self-antigen, so T cells that are 
activated in response to the pathogen are also cross-
reactive to self and lead to direct damage and further 
activation of other arms of the immune system. 
Similarly, antibodies reflecting B-cell receptor 
specificity were found to recognize both microbial and 
self-antigens [25]. This hypothesis is known as 
molecular mimicry [10,26]. It is now generally 
accepted that a single T cell can respond to various 
distinct peptides, and that different peptide/MHC 
complexes can lead to cross-reactivity by the same 
TCR as long as the complexes have similar charge 
distribution and overall shape [27-29]. This flexibility 
of TCR recognition is thought to be central to many 
immunological processes including thymic selection 
and the ability to recognize nearly all pathogen-
derived peptides. A side effect of this is the induction 
of autoimmunity by microbial antigens [7]. 
Animal models in which molecular mimicry can 
trigger autoimmune disease are abundant. These 
include: Theiler's murine encephalomyelitis virus 
(TMEV)-induced demyelinating disease (TMEV-
IDD), a model of human multiple sclerosis in which 
intracerebral TMEV infection of mice leads to an 
autoimmune demyelinating disorder 30-40 days after 
infection [21]; herpes simplex virus (HSV)-associated 
stromal keratitis, in which HSV infection leads to 
blindness secondary to corneal-antigen-specific T-cell 
responses in both humans and mice [30-33]; cytotoxic 
reactions caused by antibodies against Streptococcus 
pyogenes antigens, which  may be one mechanism to 
explain the origin of autoimmune heart disease in 
rheumatoid myocarditis [34]; infection of prediabetic 
mice with a virus expressing an H-2Kb-restricted 
Figure 1. Mechanism by which pathogens may cause autoimmunity. a) Molecular mimicry describes the activation of crossreactive T cells that recognize 
both the pathogen-derived epitopes and the self-derived epitopes. Pathogen-derived epitops are taken up by APC and presented to T cells. Activation of T 
cells results in the direct lysis of self-tissue or release of cytokines and chemokines that activate macrophages, which mediate self-tissue damage, and 
provide help to pathogen-specific B cells. The subsequent release of self-tissue antigens and their uptake by APC perpetuates the autoimmune disease. b) 
Bystander activation is the nonspecific activation of self-reactive T cells. Activation of pathogen-specific T cells leads to inflammation that damages self-
tissue in an antigen non-specific manner, and triggers activation of self-reactive T cells. c) Epitope spreading involves a persistent pathogen infection that 
causes damage to self-tissue. This results in the release of self-peptides, which are engulfed by APC and presented to self-reactive T cells. Continual damage 
and release of self-peptides results in the spread of the self-reactive immune response to multiple self-epitopes. 
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mimic ligand to a self-epitope present on beta cells, 
which accelerates the development of autoimmune 
diabetes [35]; autoimmune demyelinating disease 
associated with Semliki Forest virus (SFV) [36]; 
autoimmune myocarditis associated with coxsackie 
virus infection [37];  and murine cytomegalovirus 
[38]. T cells with low affinity for a self-antigen and 
that have escaped thymus negative selection, as would 
be the case for many self-antigen-specific responses, 
can become activated by infection with a 
microrganism containing an identical antigen, which 
provides appropriate innate immune signals, resulting 
in overt autoimmune disease. 
In keeping with the observation that specific T 
cells that have been primed by pathogens and cross-
react with self-antigens can cause autoimmunity in 
animal models, patients with autoimmune diseases 
such as systemic lupus erythematosus, rheumatoid 
arthritis and multiple sclerosis have been found to 
have higher frequencies activated self-reactive 
lymphocytes [39-42]. In multiple sclerosis, receptor 
analysis of T and B cells in central nervous system 
(CNS) tissue and in the cerebrospinal fluid (CSF) 
showed clonal expansions in both populations, 
indicating that there is clonal reactivity to a restricted 
number of disease-relevant antigens [43-45]. In 
Figure 1. Mechanism by which pathogens may cause autoimmunity. a) Molecular mimicry describes the activation of crossreactive T cells that recognize 
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cells results in the direct lysis of self-tissue or release of cytokines and chemokines that activate macrophages, which mediate self-tissue damage, and 
provide help to pathogen-specific B cells. The subsequent release of self-tissue antigens and their uptake by APC perpetuates the autoimmune disease. b) 
Bystander activation is the nonspecific activation of self-reactive T cells. Activation of pathogen-specific T cells leads to inflammation that damages self-
tissue in an antigen non-specific manner, and triggers activation of self-reactive T cells. c) Epitope spreading involves a persistent pathogen infection that 
causes damage to self-tissue. This results in the release of self-peptides, which are engulfed by APC and presented to self-reactive T cells. Continual damage 
and release of self-peptides results in the spread of the self-reactive immune response to multiple self-epitopes. 
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addition, longitudinal studies provided evidence for 
long-term persistence of individual myelin-specific T-
cell clones tracked over several years in the blood of 
patients with multiple sclerosis [46-48], indicating a 
strong, persisting memory response and/or ongoing 
autoantigen exposure at least for a subset of myelin-
reactive T cells in multiple sclerosis. These memory 
responses may reflect, at least in part, persisting clonal 
expansions of polyspecific T cells recognizing both 
self and virus antigens. For example, high viral loads 
that occur during symptomatic primary EBV infection, 
resulting in infectious mononucleosis, are associated 
with an increased risk of developing multiple sclerosis 
[49-51], and could prime these polyspecific T-cell 
responses. Accordingly, patients with multiple 
sclerosis have predominant clonal expansions of T 
cells specific for the EBV-encoded nuclear antigen 1 
(EBNA1), which is the most consistently recognized 
EBV-derived CD4+ T-cell antigen in healthy virus 
carriers, and EBNA1-specific T cells recognize myelin 
antigens more frequently than other autoantigens that 
are not associated with multiple sclerosis [52]. 
Autoimmune chronic gastritis (AIG) is an organ-
specific inflammatory disease, characterized by 
lymphocytic infiltrates in the gastric mucosa and by 
destruction of parietal cells, resulting in mucosal 
atrophy, hypochloridria, and eventually pernicious 
anemia. [53]. In most AIG patients, serum anti-parietal 
cell autoantibodies (PCAs) are detectable. The 
autoantigen recognized is the gastric H+K+ adenosine 
triphosphatase (ATPase), the proton pump, localized 
in the parietal cell canaliculi [54,55]. H+K+ ATPase is 
also the target of autoreactive T cells that infiltrate the 
gastric mucosa of AIG patients [56]. Autoimmune 
gastritis and Helicobacter pylori-associated gastric 
atrophy develop through similar mechanisms 
involving the proton pump H+K+ ATPase as 
autoantigen. Helicobacter pylori-infected patients with 
gastric autoimmunity harbor in vivo activated gastric 
Th1 CD4 cells that recognize both H+K+ ATPase and 
Helicobacter pylori antigens [57,58]. So, in genetically 
susceptible individuals, Helicobacter pylori infection 
can activate cross-reactive gastric T cells leading to 
gastric autoimmunity via molecular mimicry. 
 
Bystander activation of autoreactive cells and epitope 
spreading 
Bystander activation describes an indirect or non-
specific activation of autoimmune cells caused by the 
inflammatory environment present during infection. 
APCs that have become activated within the 
inflammatory milieu of a pathogenic infection can 
stimulate the activation and proliferation of 
autoreactive T or B cells. In this case, APC present 
self-antigen, obtained subsequent to tissue destruction 
and/or the uptake of local dying cells, to autoreactive 
cells [59,60]. In addition to autoimmune responses that 
are initially primed by APC and stimulated by 
bystander activation, additional autoantigen-specific T 
or B cells can be primed through epitope spreading 
[20], a situation in which an immune response that is 
initiated by various stimuli, including microbial 
infection, trauma, transplanted tissue or autoimmunity, 
spreads to include responses directed against a 
different portion of the same protein (intramolecular 
spreading) or a different protein (intermolecular 
spreading). Activating a broader set of T cells through 
epitope spreading is helpful in an anti-pathogen or 
anti-tumour immune response, because the pathogen 
or tumour cannot easily escape immune control with a 
single mutation in an immunogenic epitope. However, 
autoimmune disease potentially arises when spreading 
cross-reacts with self-proteins, leading to the 
destruction of self-tissue.  
Epitope spreading in animal models proceeds in an 
orderly and hierarchical manner, such that more 
immunodominant epitopes elicit responses first, 
followed by less dominant responses. This type of 
spreading has been shown in experimental 
autoimmune encephalomyelitis (EAE), a model of 
multiple sclerosis [61,62], as well as in the non-obese 
diabetic (NOD) mouse model of type 1 diabetes [63]. 
These examples document epitope spreading within 
autoantigens and to additional autoantigens. 
Mycobacterium leprae is known to preferably 
reside in Schwann cells. Antibodies to neuronal 
glycolipids such as galactocerebroside [64,65], 
ceramide [64] and asialo GM1 of myelin may be 
associated with nerve damage in leprosy patients. 
Anti-ceramide IgM antibody titre was significantly 
higher in multibacillary leprosy patients in comparison 
to both controls and paucibacillary leprosy patients 
[66]. 
An even broader form of bystander activation is 
achieved by cross-linking MHC class II molecules on 
APC with TCR comprising a certain Vβ domain by 
superantigens. T-cell populations that are stimulated in 
this manner could potentially contain a subset of T 
cells specific for a self-antigen [67]. There are 
multiple examples in which superantigens are involved 
in diseases such as EAE, arthritis and inflammatory 
bowel disease, making superantigens another 
mechanism by which bystander activation can initiate, 
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or at the least exacerbate, autoimmunity in mouse 
models [68-70]. 
Although molecular mimicry might initially prime 
autoreactive T cells, these responses could be 
amplified by superantigen-mediated expansion and by 
activation of autoantigen-specific T cells that express a 




Infections can affect the immune response in many 
ways, and mechanisms such as molecular mimicry and 
bystander activation are certainly not the only ways in 
which pathogens might trigger or accelerate 
autoimmune disease. Infection may lead to 
autoimmunity through the processing and presentation 
of cryptic antigens. In contrast to dominant antigenic 
determinants, subdominant cryptic antigens are 
normally invisible to the immune system. The 
inflammatory environment that arises after infection 
can induce increased protease production and 
differential processing of released self-epitopes by 
APC [71]. 
A recent study showed that in a spontaneous 
animal model of systemic lupus erythematosus, lipid 
raft aggregation on T cells, induced by Cholera toxin 
B from Vibrio cholerae, enhanced T-cell signalling 
and exacerbated systemic lupus erythematosus activity 
[72].  
Persistent infection of microglia with TMEV has 
been shown to cause upregulation of MHC and 
costimulatory molecules and enhance the ability of 
these cells to function as effective APC [73]. This 
shows that viral infections could also directly maintain 
autoreactive effector cells or autoantigen-presenting 
cells. 
The fact that the various mechanisms for 
infection-induced autoimmunity discussed here are 
interrelated and non-mutually exclusive make them 
both more complicated and more plausible as potential 
causes for human autoimmune disease. For example, 
molecular mimicry and adjuvant effects of pathogens 
might work early on during the development of 
autoimmune responses, whereas bystander activation 
end epitope spreading through the inflammatory 
environment of infections and/or superantigens might 
exacerbate autoimmune responses later on 
[13,26,31,74]. 
 
Induction of overt autoimmune disease 
Although several causal relationships between 
pathogen infection and autoimmunity have been 
identified in animal models and correlations have been 
drawn in human autoimmune diseases, pathogen-
derived triggers of autoimmunity have been difficult to 
identify because evidence of autoimmunity is likely to 
become clinically apparent only after a considerable 
period of subclinical autoimmune responses. 
Autoreactive adaptive immune cells are 
unavoidably present in the periphery in humans and 
animals. These cells can exist because their cognate 
self-antigen was not expressed in the thymus and the 
antigen will therefore only become apparent to the 
immune system after tissue destruction as a result of 
infection or trauma. Alternatively, whereas many 
autoreactive T cells are deleted in the thymus during 
development, some T cells that make their way to the 
periphery might be highly specific for a microbial 
antigen, but also have lesser affinity for a self-antigen. 
The presence of autoreactive cells in the periphery, 
however, does not necessarily predispose for clinical 
autoimmune disease. 
It is clear that, in many cases, an infection is 
necessary for the development of overt disease, even 
when abundant autoreactive T cells are present. The 
potential for the development of overt disease is 
clearly dependent on the presence of autoreactive T 
cells. However, whether overt disease actually occurs 
can depend on various other coincident events, 
including the number of autoreactive T cells present, 
the avidity and affinity of these cells (determined by 
co-receptor expression and binding to MHC/peptide 
complexes, respectively), and the presence of innate 
inflammatory signals required for activation and 
differentiation of those T cells to a pathogenic 
phenotype. Despite the requirement for all these 
elements, it is clear that they do not need to happen at 
the same time or in the same place to elicit 
autoimmune disease. In many animal models, 
autoimmune responses are triggered during the initial 
or acute response to an infection, and autoimmune 
disease occurs exclusively in the infected organ, such 
as during corneal HSV infection leading to stromal 
keratitis [13,30,31]. However, none of the proposed 
mechanisms for the development of infection-induced 
autoimmunity excludes the possibility that disease can 
occur temporally and/or spatially distal from the site of 
the initiating infection. Animal models that allow 
investigators to study this aspect of infection-induced 
autoimmune disease are few, but they might provide 
important insights relevant to human disease. 
Autoimmune CNS demyelinating disease can be 
triggered by molecular mimicry when the pathogen 
containing the mimic epitope does not infect the CNS 
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itself. When mice that express an LCMV protein in the 
CNS were peripherally infected with LCMV, 
autoimmune responses occurred in the CNS despite 
the fact that LCMV was not detectable in that organ 
[75]. 
Finally it is of interest to emphasize that the 
preferential homing of primed antiviral or antibacterial 
T cells might also falsely implicate pathogens in the 
immunopathology of autoimmune diseases. Lytic EBV 
infection was suspected to contribute to rheumatoid 
arthritis after it was found that lytic EBV antigen-
specific T cells were enriched in inflamed joints [76]. 
It was later found that these lytic EBV antigenspecific 
T cells were home to a variety of autoimmune 
inflamed tissues [77], including knees affected by 
rheumatoid arthritis, eyes of patients with uveitis, and 
the brains of patients with multiple sclerosis. These 
data were interpreted as primarily reflecting the 
migration of EBV-specific T cells in response to 
inflammatory chemokines, such as the CXCR3 ligand 
CXCL10, rather than a direct involvement of EBV-




Besides genetic predisposition to autoimmunity, 
environmental factors are known to be involved in the 
initiation and promotion of autoimmune diseases. 
Among these, viral and bacterial infections are the 
main candidate environmental factors due to their 
capacity to elicit strong immune activation and to 
induce autoimmune diseases in animal models, as well 
as the correlation of several pathogens with 
autoimmune diseases in humans. These studies 
suggest that pathogens can trigger autoimmunity 
through molecular mimicry and their adjuvant effects 
during initiation of disease, and can promote 
autoimmune responses through bystander activation or 
epitope spreading via inflammation and/or 
superantigens. However, an association of 
dysregulated antiviral immune responses with a given 
autoimmune disease has to be interpreted with caution, 
because these can be differently primed in individuals 
with ongoing autoimmune disease or with a genetic 
predisposition to autoimmune disease. Furthermore, 
the autoimmune disease can alter virus infection by 
affecting its host cells, and might lead to redistribution 




The news that you never want to hear: the passing of a good friend, 
mentor and scientist. Gianfranco Del Prete said goodbye to this 
world in November 2010. 
Here we would like to remember Gianfranco Del Prete not just 
because he was a full professor of medicine in the University of 
Florence or because of his large number of important publications 
in the immunology field, where one of his major research goals of 
was the study of important scientific issues related to developing 
countries. Here we would like to remember Gianfranco as a person 
able to dedicate himself to research, until the end of his life, with 
always a very impressive energy, passion and curiosity. He was 
straightforward but always honest and he had the gift of being able 
to involve everyone in a magical feeling: the feeling of science … 
where you think that with your job, your mind, doing research, 
working hard with passion, you can improve someone else’s life 
… you can give new knowledge to the community. A fruitful life 
of achievement makes Gianfranco Del Prete a Man to be 
remembered in science. 
For all you gave us and to the world it is with great emotion that 
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